We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) closed the most recent trading day at $9.26, moving -1.59% from the previous trading session. This move lagged the S&P 500's daily gain of 1.05%. Elsewhere, the Dow gained 1.02%, while the tech-heavy Nasdaq added 1.66%.
Heading into today, shares of the company had lost 34.97% over the past month, lagging the Medical sector's loss of 1.73% and the S&P 500's loss of 2.76% in that time.
TEVA will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0.58, down 25.64% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $4.27 billion, down 9.15% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $2.37 per share and revenue of $17.18 billion. These totals would mark changes of -18.84% and -8.87%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for TEVA. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.49% lower. TEVA is holding a Zacks Rank of #3 (Hold) right now.
Digging into valuation, TEVA currently has a Forward P/E ratio of 3.97. This represents a discount compared to its industry's average Forward P/E of 6.8.
It is also worth noting that TEVA currently has a PEG ratio of 1.08. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. TEVA's industry had an average PEG ratio of 0.99 as of yesterday's close.
The Medical - Generic Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 176, which puts it in the bottom 32% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know
Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) closed the most recent trading day at $9.26, moving -1.59% from the previous trading session. This move lagged the S&P 500's daily gain of 1.05%. Elsewhere, the Dow gained 1.02%, while the tech-heavy Nasdaq added 1.66%.
Heading into today, shares of the company had lost 34.97% over the past month, lagging the Medical sector's loss of 1.73% and the S&P 500's loss of 2.76% in that time.
TEVA will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0.58, down 25.64% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $4.27 billion, down 9.15% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $2.37 per share and revenue of $17.18 billion. These totals would mark changes of -18.84% and -8.87%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for TEVA. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.49% lower. TEVA is holding a Zacks Rank of #3 (Hold) right now.
Digging into valuation, TEVA currently has a Forward P/E ratio of 3.97. This represents a discount compared to its industry's average Forward P/E of 6.8.
It is also worth noting that TEVA currently has a PEG ratio of 1.08. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. TEVA's industry had an average PEG ratio of 0.99 as of yesterday's close.
The Medical - Generic Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 176, which puts it in the bottom 32% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.